Subscribe
man_at_mouse
man_at_mouse / iStockphoto.com
7 February 2019Biotechnology

Victory for Mayo in neurological disorder patent dispute

In a victory for Mayo Collaborative Services, a US Court has ruled that four claims in a patent, of which Athena Diagnostics is the exclusive licensee, are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit refuses to rehear Athena dispute; judges call for reform
4 July 2019   The US Court of Appeals for the Federal Circuit has upheld a win for Mayo Collaborative Services after it denied Athena Diagnostics’ petition to have a neurological patent dispute reheard en banc.
Big Pharma
Athena asks for rehearing on invalidated neurological disorder patent
9 April 2019   Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Americas
Federal Circuit refuses to rehear Athena dispute; judges call for reform
4 July 2019   The US Court of Appeals for the Federal Circuit has upheld a win for Mayo Collaborative Services after it denied Athena Diagnostics’ petition to have a neurological patent dispute reheard en banc.
Big Pharma
Athena asks for rehearing on invalidated neurological disorder patent
9 April 2019   Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More on this story

Americas
Federal Circuit refuses to rehear Athena dispute; judges call for reform
4 July 2019   The US Court of Appeals for the Federal Circuit has upheld a win for Mayo Collaborative Services after it denied Athena Diagnostics’ petition to have a neurological patent dispute reheard en banc.
Big Pharma
Athena asks for rehearing on invalidated neurological disorder patent
9 April 2019   Athena Diagnostics has asked the US Federal Circuit to revisit its decision earlier this year, which found four claims in one of its patents to be invalid.
Americas
Amerigen loses patent case against UCB at Federal Circuit
14 January 2019   US-based Amerigen Pharmaceuticals has lost in its bid to prove that claims in a patent owned by biopharmaceutical company UCB were covered by a prior invention.

More features

Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university